Peptide Atlas · Peptide

Davunetide

Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in preclinical studies; in a 52-week phase 2/3 trial in 313 people with progressive supranuclear palsy it did not differ from placebo on either primary measure.

established

provisional
8 aa
PubChem 9832404
2 citations
0 discussions
0 followers
ADNF fragment
AL-108
AL-208
NAP
NAPVSIPQ
activity-dependent neuroprotective protein fragment

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

No protocol has enough distinct humans behind it to be a protocol. One person saying it twice is still one person.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.